Institute of Neurodegenerative Diseases (@imn-bordeaux.bsky.social)

How can we improve the differential diagnosis of neurodegenerative diseases with AI-enhanced MRI analyses? How can we make the interpretation of results easier for clinicians? 📰 New article from @vincentplanche.bsky.social and al. For more details : alzres.biomedcentral.com/articles/10....

loading . . .

petBrain: a new pipeline for amyloid, Tau tangles and neurodegeneration quantification using PET and MRI - Alzheimer's Research & Therapy Introduction Quantification of amyloid plaques (A), neurofibrillary tangles (T2), and neurodegeneration (N) using PET and MRI is critical for Alzheimer’s disease (AD) diagnosis and prognosis. Existing pipelines face limitations regarding processing time, tracer variability handling, and multimodal integration. Methods We developed petBrain, a novel end-to-end processing pipeline for amyloid-PET, tau-PET, and structural MRI. It leverages deep learning-based segmentation, standardized biomarker quantification (Centiloid, CenTauR, HAVAs), and simultaneous estimation of A, T2, and N biomarkers. It is implemented in a web-based format, requiring no local computational infrastructure and software usage knowledge. Results petBrain provides reliable, rapid quantification with results comparable to existing pipelines for A and T2, showing strong concordance with data processed in ADNI databases. The staging and quantification of A/T2/N by petBrain demonstrated good agreements with CSF/plasma biomarkers, clinical status and cognitive performance. Discussion petBrain represents a powerful open platform for standardized AD biomarker analysis, facilitating clinical research applications. https://alzres.biomedcentral.com/articles/10.1186/s13195-025-01839-y